Back HIV Prevention

IAS 2017: Why Curing Cancer May Be Like Curing HIV -- and May Be As Difficult

For the last few years, a specialist symposium on HIV cure research has preceded the annual International AIDS Society meetings, and this year was no exception, with a 2-day forum at the Curie Institute in Paris before the opening of the 9th IAS Conference on HIV Science (IAS 2017).

alt

Read more:

IDWeek 2017: Long-Acting Monoclonal Antibody Effective Against Multidrug-Resistant HIV

Ibalizumab, a long-acting monoclonal antibody that prevents HIV from entering cells, maintained viral suppression for a year in people with highly resistant HIV and limited treatment options, according to a presentation at the IDWeek 2017 conference last week in San Diego.

alt

Read more:

IAS 2017: Doravirine Combo Pill Looks Good for Initial HIV Treatment

A single-tablet regimen containing the next-generation NNRTI doravirine reduced HIV viral load as much as an efavirenz-based coformulation, but it had a more favorable side effect profile, according to results from the DRIVE-AHEAD studypresented at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.

alt

Read more:

IDWeek 2017: Single-Tablet Protease Inhibitor Regimen Maintains Viral Suppression for a Year

People who switched from a multi-pill antiretroviral regimen to the first 1-pill, once-daily regimen that includes a protease inhibitor maintained undetectable viral load for a year, according to a report at the IDWeek 2017 conference last week in San Diego.

alt

Read more:

IAS 2017: Boosted Darunavir Plus Lamivudine Matches 3-Drug Regimen

A combination of darunavir/ritonavir and lamivudine was just as effective as the same combination plus tenofovir, according to 24-week results from the ANDES study, presented at the recent 9th IAS Conference on HIV Science (IAS 2017) in Paris.

alt

Read more:

Virally Suppressed People Have "Effectively No Risk" of Transmitting HIV, Says CDC

The US Centers for Disease Control and Prevention (CDC) announced on September 27, National Gay Men’s HIV/AIDS Awareness Day, that HIV diagnoses had fallen among white gay and bisexual men and remained stable among African-American gay men between 2010 and 2014, its last complete year of figures.

alt

Read more:

IAS 2017: PrEP Use in U.S. Exceeds 100,000 in Gilead Pharmacy Survey

An estimated 120,000 people in the U.S. have started Truvada (tenofovir/emtricitabine) for pre-exposure prophylaxis (PrEP) since 2012, according to the latest findings from a survey of retail and mail-order pharmacies by Gilead Sciences, presented at the recent 9th IAS Conference on HIV Science (IAS 2017) in Paris.

alt

Read more:

IAS 2017: Cancer Research May Offer Clues for HIV Cure Research -- and Vice Versa

There is a growing overlap between the fields of cancer and HIV cure research, and approaches that help fight one disease may offer clues about the other. This convergence was the theme of the HIV Cure and Cancer Forum preceding the International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris -- the first time cancer has joined the HIV cure agenda.

alt

Read more:

IAS 2017: Trans Women Wary of Antiretroviral Drug and Hormone Interactions

Transgender women with HIV may be hesitant to use antiretroviral therapy (ART) or not take it as prescribed because of concerns about drug interactions with feminizing hormones, according to a presentation at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.alt

Read more:

No New HIV Infections Among Kaiser PrEP Users, But Cascade Shows Missed Opportunities

No new HIV infections have occurred among nearly 5000 people who started Truvada for pre-exposure prophylaxis (PrEP) in the Kaiser Permanente Northern California health system, according to a letter in the July 29 edition of Clinical Infectious Diseases.

alt

Read more:

IAS 2017: Acute Kidney Injury Uncommon on Tenofovir, No Link Seen to Bone Breaks

Doctors need to monitor patients regularly for kidney function if they are taking tenofovir disoproxil fumarate (TDF), especially if combined with ritonavir, according to a report at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.

alt

Read more:

IAS 2017: Experts Agree that Intermittent Oral PrEP Probably Won't Work for Women

Two presenters at the recent International AIDS Society Conference on HIV Science (IAS 2017) in Paris told delegates that both trial results and analysis of drug levels support the idea that event-related or "on demand" pre-exposure prophylaxis (PrEP) might not be sufficiently powerful to prevent HIV infection in women and trans men via vaginal sex.

alt

Read more:

IAS 2017: Aim for $90-$90-$90 Target on HIV, Hepatitis, and TB Drug Prices, Study Says

HIV, hepatitis B and C, and tuberculosis (TB) can each be treated for less than $90 a year where generic drugs can be made available, Dzintars Gotham of Imperial College London reported at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.

alt

Read more:

IAS 2017: Switch from Boosted Protease Inhibitor to Dolutegravir Reduces Lipids in People with HIV

Switching from a boosted protease inhibitor to the integrase inhibitor dolutegravir (Tivicay) was associated with lipid reductions in people with HIV at higher risk of heart disease, according to results of the NEAT 022 study presented at the recent 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris.

alt

Read more:

IAS 2017: People with HIV Are at Risk for Liver Fibrosis and Steatosis

Metabolic syndrome, type 2 diabetes, and obesity are risk factors for the development of liver fibrosis and steatosis (liver fat accumulation) in people living with HIV, including those who do not have viral hepatitis coinfection, according to research presentedat the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.alt

Read more:

IAS 2017: Who Are Trans Women Acquiring HIV From?

There is a lot we don't know about trans women's HIV risk, why they are so vulnerable to HIV, and who trans women are acquiring HIV from. A study presented at the recent 9th International AIDS Society Conference on HIV Science (IAS 2017) attempted to answer these questions, but in the process uncovered another mystery: is there a hidden population of heterosexual men who have sex with trans women and who are themselves at high risk of acquiring and transmitting HIV? One thing the study did make clear, however, is that a lot of HIV infections among trans women may be due to injecting drugs rather than sex.

alt

Read more:

IAS 2017: Medical Male Circumcision for HIV Prevention Has Benefits for Women Too

South African women whose most recent sexual partner was circumcised are less likely to have HIV, suggesting that voluntary medical male circumcision programs have benefits for women, too, according to a study presented to the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.

alt

Read more:

CDC Continues to Recommend Annual HIV Testing for Gay Men

The U.S. Centers for Disease Control and Prevention (CDC) recently reaffirmed its recommendation that sexually active gay and bisexual men should undergo at least annual HIV screening, according to a report in the August 11 edition of the CDC's Morbidity and Mortality Weekly Report. However, some local providers advise more frequent HIV and sexually transmitted infection tests.

alt

Read more:

IAS 2017: VRC01 Antibody Can Delay But Not Prevent HIV Rebound

A broadly neutralizing antibody modestly delayed the resurgence of viral replication following interruption of antiviral therapy (ART) started during very early infection, but all study participants ultimately experienced viral rebound, according to results presented at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.

alt

Read more:

San Francisco Annual Report Shows Continued Drop in HIV Infections

The San Francisco Department of Public Health has released its HIV Epidemiology Annual Report for 2016, showing that the number of new infections continues to decline, with decreases seen across demographic groups. Homeless people, however, have higher rates of infection and poorer treatment outcomes.

alt

Read more:

IAS 2017: Novel Long-Acting Drug Shows Promise for HIV Treatment and PrEP

A single oral dose of MK-8591, a long-acting antiretroviral in a novel drug class, suppressed HIV for 7 days in an early clinical trial, and the drug also appears to protect monkeys from rectal infection with an HIV-like virus, researchers reported at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.

alt

Read more: